Heart Valve Disease: How to Choose Between Interventional Treatment and Open-Heart Surgery?

Introduction

Heart valve disease is a class of conditions where heart valves (such as the aortic or mitral valve) cause hemodynamic abnormalities due to stenosis or regurgitation, significantly impacting quality of life. According to statistics, the prevalence of heart valve disease among people aged over 65 in China is approximately 13%, with aortic stenosis being the most common. With an aging population, this number continues to rise.

Upon diagnosis, patients often face a critical decision: whether to choose minimally invasive interventional treatment (such as TAVR) with faster recovery, or traditional open-heart surgery with proven efficacy and a long history. This article provides a comprehensive comparative analysis from the perspectives of indications, risks, recovery, and long-term outcomes, helping you and your doctor jointly determine the optimal treatment strategy.

1. Core Differences Between the Two Treatment Approaches

Interventional Treatment (Transcatheter Valve Replacement/Repair): Through the femoral artery or apical approach, a compressed valve catheter is delivered to the lesion site and released to replace the native valve. Representative technologies include transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (MitraClip). No open chest or cardiopulmonary bypass is required; the procedure takes approximately 1-2 hours, with a postoperative hospital stay of 3-5 days. Open-Heart Surgery (Valve Replacement/Repair Under Cardiopulmonary Bypass): Requires a median sternotomy or minimally invasive small incision, establishment of cardiopulmonary bypass, direct exposure of the heart, removal of the diseased valve, and implantation of a mechanical or bioprosthetic valve. The procedure takes 3-5 hours, with a postoperative hospital stay of 7-14 days and a longer recovery period.

2. Indications: Who Can Choose Interventional Treatment?

Interventional treatment was initially used for high-risk patients or those unable to tolerate open-heart surgery, but with technological advancements, indications have expanded to include intermediate- and low-risk populations. According to the 2023 European Society of Cardiology guidelines:

Aortic Stenosis: For high-risk patients aged ≥75 years with an STS score ≥8%, TAVR is recommended; for patients aged <75 years with low risk (STS <4%), open-heart surgery remains the first-line choice, but TAVR can also be an alternative.

Mitral Regurgitation: MitraClip is suitable for severe primary or secondary regurgitation, particularly in elderly patients or those with left ventricular dysfunction.

Bioprosthetic Valve Failure: Valve-in-valve interventional techniques can be used to address degeneration of previously implanted bioprosthetic valves.

Open-heart surgery is more suitable for: younger patients (<65 years) who wish to receive a mechanical valve for long-term durability; those with complex multi-valve disease, coronary artery disease requiring bypass grafting, or valve anatomy unsuitable for interventional procedures (e.g., excessively large annulus, severe calcification).

3. Trauma and Recovery: Interventional Treatment Excels, but Trade-offs Exist

The advantages of interventional treatment are evident: no chest opening, minimal trauma, less bleeding, reduced postoperative pain, shorter ICU stay (typically 1 day), and total hospital stay reduced by half. Patients can return to normal activities within 2-4 weeks postoperatively, whereas open-heart surgery requires more than 3 months.

However, interventional treatment is not without drawbacks: the rate of postoperative pacemaker implantation (approximately 10-15%) is higher than that of open-heart surgery (5%), the incidence of paravalvular leakage is about 3-5%, and long-term durability data are less robust than those for surgical valves (10-year durability of interventional valves is approximately 90%, while surgical bioprosthetic valves have 20-year durability of about 80%). Additionally, the cost of interventional treatment is generally higher than that of open-heart surgery (especially with imported valves), although domestic medical insurance has partially covered some consumables.

4. Long-Term Outcomes: Open-Heart Surgery Offers Greater Durability, Interventional Treatment Is More Minimally Invasive

The long-term outcomes of open-heart surgery have been validated over decades: the 20-year survival rate for mechanical valves is approximately 60%, and the 10-year freedom from reoperation for bioprosthetic valves is about 85%. Since its introduction to China in 2011, interventional treatment has achieved a 5-year survival rate of approximately 70%, comparable to open-heart surgery in high-risk patients, but more data are needed for intermediate- and low-risk populations.

The key to choosing lies in individualized assessment:

Age: For patients <65 years, open-heart surgery (mechanical valve) is recommended to avoid reoperation; for those >75 years, interventional treatment is preferred to reduce trauma.

Comorbidities: For patients with severe pulmonary dysfunction, liver cirrhosis, or a history of radiation, interventional treatment is safer.

Valve Type: Mechanical valves require lifelong anticoagulation, while bioprosthetic valves do not but may degenerate.

5. International Perspective: Technological Frontiers and Medical Care Options

Currently, the global treatment of heart valve disease is trending toward "minimally invasive and individualized" approaches. Taking TAVR as an example, newer-generation valves are retrievable, repositionable, and have lower paravalvular leakage rates. In China, centers such as Beijing Fuwai Hospital and Shanghai Zhongshan Hospital perform over 500 TAVR procedures annually, with technical maturity on par with international standards.

For international patients, the advantages of seeking medical care in China include:

Cost: The total cost of TAVR is approximately 150,000-250,000 RMB, only one-third of that in the United States (50,000-80,000 USD);

Waiting Time: Surgical scheduling in China typically takes 2-4 weeks, compared to 3-6 months in the U.S.;

Multidisciplinary Team: Cardiologists, cardiac surgeons, and imaging specialists collaborate to develop the optimal plan.

You can learn more about the detailed process through our medical services or obtain a personalized quote using our cost estimator. Our team can assist with specialist appointments, translation services, visas, and postoperative follow-up.

Recommendations for International Patients

Comprehensive Evaluation: Ensure completion of echocardiography, CT angiography, and coronary angiography to determine the type and severity of valve disease.

Multidisciplinary Consultation: Seek combined opinions from cardiology and cardiac surgery departments; do not rely solely on a single specialty.

Weigh Risks and Benefits: Based on age, life expectancy, and comorbidities, list the pros and cons of both options and discuss them with family members.

Choose an Experienced Center: Centers performing >100 procedures per year have significantly lower complication rates.

Plan Postoperative Rehabilitation: After interventional treatment, dual antiplatelet therapy is required for 3-6 months; after open-heart surgery, cardiopulmonary rehabilitation is needed. Prepare in advance.

Regardless of the chosen approach, the treatment of heart valve disease is highly mature, with a 5-year survival rate exceeding 80%. The key is timely medical attention and informed decision-making. For further assistance, feel free to contact us, and our international medical team will provide professional support.